Pulse Biosciences, Inc $PLSE Stock Position Lowered by Inspire Investing LLC

Inspire Investing LLC lessened its position in Pulse Biosciences, Inc (NASDAQ:PLSE) by 5.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,624 shares of the company’s stock after selling 1,133 shares during the quarter. Inspire Investing LLC’s holdings in Pulse Biosciences were worth $348,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in PLSE. Farther Finance Advisors LLC increased its stake in Pulse Biosciences by 24.6% in the 1st quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company’s stock valued at $143,000 after buying an additional 1,778 shares during the period. Deutsche Bank AG increased its stake in Pulse Biosciences by 65.1% in the 4th quarter. Deutsche Bank AG now owns 16,795 shares of the company’s stock valued at $292,000 after buying an additional 6,625 shares during the period. Rhumbline Advisers increased its stake in Pulse Biosciences by 6.3% in the 1st quarter. Rhumbline Advisers now owns 27,375 shares of the company’s stock valued at $440,000 after buying an additional 1,614 shares during the period. Bank of America Corp DE increased its stake in Pulse Biosciences by 0.4% in the 4th quarter. Bank of America Corp DE now owns 788,454 shares of the company’s stock valued at $13,727,000 after buying an additional 2,884 shares during the period. Finally, GAMMA Investing LLC increased its stake in Pulse Biosciences by 2,203.1% in the 1st quarter. GAMMA Investing LLC now owns 6,034 shares of the company’s stock valued at $97,000 after buying an additional 5,772 shares during the period. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Insider Activity at Pulse Biosciences

In other Pulse Biosciences news, Director Robert W. Duggan purchased 34,659 shares of the company’s stock in a transaction dated Wednesday, September 10th. The shares were bought at an average price of $14.66 per share, for a total transaction of $508,100.94. Following the purchase, the director directly owned 47,551,200 shares in the company, valued at $697,100,592. This trade represents a 0.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 74.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer started coverage on shares of Pulse Biosciences in a research note on Monday, July 7th. They issued an “outperform” rating and a $22.00 price objective on the stock. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, Pulse Biosciences has an average rating of “Buy” and a consensus price target of $22.00.

Pulse Biosciences Stock Down 3.8%

Shares of PLSE opened at $14.52 on Monday. The company’s fifty day moving average is $15.49 and its 200-day moving average is $16.16. Pulse Biosciences, Inc has a 12 month low of $13.77 and a 12 month high of $25.00. The firm has a market cap of $977.20 million, a price-to-earnings ratio of -13.83 and a beta of 1.68.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02).

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.